ライフサイエンスコーパス: pg

1 than in the cataract controls (16.6 +/- 14.0 pg/mL; P = .002).

2 pg IFNG/mL (inter-quartile range, 43.3-151.0 pg IFNG/mL), whereas subjects without CRC had a median l

3 (n = 27) vs survival (n = 106) (median, 36.0 pg/mL vs 10.4 pg/mL, respectively, P < .001).

4 compared to those with undetectable VL (38.0 pg/mL) (P < .0001, U test).

5 -3)) compared to Bizerte ( approximately 6.0 pg m(-3)).

6 RC by colonoscopy had a median level of 86.0 pg IFNG/mL (inter-quartile range, 43.3-151.0 pg IFNG/mL)

7 were higher in Marseille ( approximately 9.0 pg m(-3)) compared to Bizerte ( approximately 6.0 pg m(-

8 growth factor (VEGF) (Group I: 157.0 (154.0) pg/mL, Group II: 98.0 (20.25) pg/mL, P = .01); and vitam

9 ) pg/g lipid and PCDD TEQ was 8.7 (1.0-36.0) pg TEQ/g lipid.

10 ion of 0.2 pg/h for mammalian cells and 0.02 pg/h for bacteria.

11 for IL6: median, 1.91 pg/mL; IQR, 1.21-3.02 pg/mL vs median, 2.81 pg/mL; IQR, 1.65-4.97 pg/mL, P < 0

12 oducibility and a limit of detection of 2.05 pg.mL(-1).

13 aerosol, we show that fluxes as low as 0.068 pg s(-1) can be detected over a 50 s period, equivalent

14 d to the European coastal site (1.0 and 0.08 pg m(-3), respectively).

15 pg/mL vs median, 2.25 pg/mL; IQR, 1.63-3.08 pg/mL, P < 0.001; and for IL6: median, 1.91 pg/mL; IQR,

16 , while 1.0, 0.10, 3.3, 0.33, 0.88, and 0.09 pg kg bw(-1) day(-1) were found in personal air for PFHx

17 pg/mL with a linear detection range from 0.1 pg/mL to 1 ng/mL PSA.

18 reported to have a limit of detection of 0.1 pg/mL with a linear detection range from 0.1 pg/mL to 1

19 NfL levels were higher in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than

20 ects without CRC had a median level of 298.1 pg IFNG/mL (inter-quartile range, 100.4-920.2 pg IFNG/mL

21 tration in the healthy cohort (n=93) was 3.1 pg/mL, and 14% (36/249) of UCSF cohort and 26% (102/387)

22 optimum diagnostic cutoff of DKK-1 was 583.1 pg/mL with the area under curve (AUC) 0.76 (95% CI, 0.70

23 amples of PVDF powder were typically below 1 pg/g for (232)Th and 2 pg/g for (238)U, corresponding to

24 mit of detection (LOD) of 1E-4 ng/mL (i.e. 1 pg/mL) at 7% CV (coefficient of variation) for cTnT in H

25 anodine able to induce priming in females (1 pg) is 1/100,000(th) that needed in males (100 ng), an e

26 crements), 1.06; 95% CI, 1.03-1.09 and HRs(1 pg/ml increments), 1.03; 95% CI, 0.99-1.06, respectively

27 ements), 1.19; 95% CI, 1.08-1.32; IL6: HRs(1 pg/ml increments), 1.06; 95% CI, 1.03-1.09 and HRs(1 pg/

28 onfidence interval (CI), 1.13-1.36 and HRs(1 pg/ml increments), 1.19; 95% CI, 1.08-1.32; IL6: HRs(1 p

29 ted models: TNF-alpha: hazard ratios (HRs)(1 pg/ml increments), 1.24; 95% confidence interval (CI), 1

30 2 x 10(-6) RIU for bulk refractive index, 1 pg/mm(2) for surface-adsorbed mass, and approximately 10

31 unds were detected at low concentrations (<1 pg/L).

32 00 ng/mL with a minimum detection limit of 1 pg/mL B. anthracis Sap antigen.

33 The Genedrive assay had an LOD of 1 pg/mul (100 genomic DNA copies/reaction).

34 om crude bacterial cell lysate spiked with 1 pg mL(-1) template DNA without requiring the use of orga

35 e median (range) for TCDD was 2.9 (0.4-12.1) pg/g lipid and PCDD TEQ was 8.7 (1.0-36.0) pg TEQ/g lipi

36 ceiving in a given cycle (hazard ratio per 1-pg/mL increase, 0.999; 95% CI, 0.997-1.001).

37 syndrome (8.3 [1.4-25.1] vs. 3.6 [0.6-17.1] pg/mL, p < 0.01), whereas high mobility group protein B1

38 id not differ between patients (6.4 [0-18.1] pg/mL) and controls (4.8 [0.3-17.7] pg/mL).

39 ple (18 pl per pulse) was achieved with a 10 pg ml(-1) cocaine sample.

40 endogenous proteins at the approximately 10 pg/mL level in nondepleted serum and at <10 copies per c

41 Although DAMGO (10 pg intra-LC) increased the number of trials to reach cri

42 The selective MOR agonist, DAMGO (10 pg), completely inhibited LC discharge of male but not f

43 urface with improved limit of detection ( 10 pg/mL) over standard colorimetric ELISA methods.

44 , E2 was above the postmenopausal range (>10 pg/mL) in 28 of 76 women (37%).

45 o pmol/L, multiply by 3.671) and at least 10 pg/mL above baseline after treatment initiation on 2 con

46 ing coarse-mode aerosol, mass changes of <10 pg can be detected by the sampling droplet as discrete c

47 etection of carbendazim within a range of 10 pg/mL-10 ng/mL with a limit of detection of 8.2 pg/mL.

48 stradiol (E2), defined as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3.671) and at l

49 ogenic strains at a concentration down to 10 pg mL(-1) with a large dynamic range of 0.01-100 ng mL(-

50 Fiber sections (2.5 mm) were loaded with 10 pg of New Brunswick Laboratory certified reference mater

51 e achieved, with procedural blanks of 10-100 pg, negligible with regard to the amounts of analytes pr

52 ip-based sample at a concentration below 100 pg m(-3).

53 hospital plasma, and prehospital fluids (100 pg/mL higher adrenaline predicted 2.75 ng/mL higher synd

54 The detection dynamic range is from 100 pg/ml to 1 microg/ml.

55 elevated hs-cTnI (>26.2 ng/L) and BNP (>100 pg/mL) were also studied.

56 e demonstrate that single droplets with <100 pg of analyte can easily be studied using single droplet

57 remely low abundance proteins (e.g., </= 100 pg/mL in blood plasma/serum) using targeted proteomics a

58 -terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuria, no family history of coronar

59 of a target mutation in the presence of 100 pg/muL of wild-type DNA, corresponding to detecting muta

60 ith intact parathyroid hormone less than 100 pg/mL, were included as controls.

61 nin I, a biomarker of cardiac disease to 100 pg/ml within 4 mins, which is faster, and as sensitive a

62 ethod detection limit ranging from 10 to 100 pg/mL.

63 ronolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 25

64 hieving a target NT-proBNP of less than 1000 pg/mL.

65 pared with control individuals (median, 1094 pg/mL; range, 845-1305 pg/mL; P = .05).

66 ted with interleukin-18 concentration (-0.11 pg/mL, 95% CI: -0.19, -0.04).

67 , up to 3400 pg L(-1) of FOSA and up to 1100 pg L(-1) of PFOS were measured in Brazilian surface wate

68 524 pg/ml CSF, with 37 controls of <4 to 115 pg/ml CSF.

69 ntrations ranged from below detection to 119 pg m(-3) for ethanol, 2-chloro-, phosphate (3:1) (TCEP).

70 natriuretic peptide increased by 88 +/- 120 pg/mL during follow-up but decreased significantly by 77

71 n estimated limit of detection as low as 120 pg/cm(2), a linear range of up to 7 ng/cm(2), and a regr

72 level considered to exclude disease (</=125 pg/mL) in 18% of subjects with HFpEF.

73 d with control participants (1047 [809-1265] pg/mL) (P < .001 for all) and in the AD dementia group c

74 Mean (range) baseline E2 was 20 (<2 to 127) pg/mL.

75 (1095-3266 pg/mL) in those with AF and 1271 pg/mL (703-2569 pg/mL) in those without (P<0.0001).

76 n tissue PGE2 concentration was 1005 +/- 129 pg/mL before treatment and 241 +/- 41 pg/mL after treatm

77 to correctly quantify DNA with more than 13 pg/nL HA, whereas Immolase (1 U) could handle up to 375

78 sing a higher PTH threshold greater than 130 pg/mL.

79 air concentrations (43 pg/kg bw/d versus 130 pg/kg bw/d).

80 viduals (median, 1094 pg/mL; range, 845-1305 pg/mL; P = .05).

81 y 60% (from 1208.1 +/- 186 to 1934.4 +/- 135 pg/ml; p < 0.0001) and 63% (1970.3 +/- 95 pg/ml; p < 0.0

82 )) compared to Marseille ( approximately 140 pg TEQ m(-2) y(-1)), with potential implications for aqu

83 asthma from health were identified as >1482 pg/ml (IL) and >1619 pg/ml (UK).

84 OA concentrations in the PML (mean 32 +/- 15 pg/L).

85 deep water concentrations below 200 m (5-15 pg/L) were slightly higher than measurements (<5 pg/L),

86 6 orders of magnitude from approximately 15 pg/g down to approximately 25 ag/g.

87 al range for sensitive assay is less than 15 pg/mL (< 50 pmol/L).

88 rmal platelets showed that LPS alone (50-150 pg/mL) did not stimulate platelets but amplified platele

89 p24 antigen from spiked serum specimens (150 pg/mL) much more quickly than Dynabeads, which resulted

90 5 and pre-LT BNP concentration exceeding 155 pg/mL had a 27% ICU mortality rate (P = 0.03).

91 25 and pre-LT serum BNP level less than 155 pg/mL survived, whereas patients combining MELD score ex

92 serum level to predict ICU mortality was 155 pg/mL with a negative predictive value of 99%.

93 ed in personal air were 1970, 7170, and 1590 pg m(-3) for 6:2, 8:2, and 10:2 FTOH, respectively, whic

94 rum estradiol was checked and returned at 16 pg/mL (61 pmol/L); postmenopausal range for sensitive as

95 ntly exceed the Water Quality Criteria of 16 pg/L for the sum of PCBs due in part to atmospheric depo

96 ere identified as >1482 pg/ml (IL) and >1619 pg/ml (UK).

97 /mL) and DOPAC from 0.5-100 ng/mL (LOD = 162 pg/mL).

98 sion to AD during follow-up; 1182 [923-1687] pg/mL), and progressive MCI group (MCI with progression

99 dementia during follow-up; 1336 [1061-1693] pg/mL) compared with control participants (1047 [809-126

100 ricella-zoster virus-associated (5386 [1778] pg/mL) uveitis.

101 r than nighttime concentrations (280 +/- 180 pg m(-3); p = 0.03).

102 urately identified subjects with CRC was 181 pg/mL.

103 edian (Q1, Q3) levels of NT-proBNP were 1817 pg/mL (1095-3266 pg/mL) in those with AF and 1271 pg/mL

104 r in the AD dementia group (1479 [1134-1842] pg/mL), stable MCI group (no progression to AD during fo

105 to account for 34-59% ( approximately 11-19 pg/L) of measured PFOA concentrations in the PML (mean 3

106 tients with elevated baseline hs-TnT>/=15.19 pg/mL (upper tertile) demonstrated a significant (P=0.04

107 versus 7.7 per 100 patient-years; 1000-1999 pg/mL, 9.8 versus 11.4 per 100 patient-year; 2000-2999 p

108 absolute LOD of few picograms for Pb and 0.2 pg for Ag.

109 dian levels at the African edge (2.1 and 0.2 pg m(-3), respectively) compared to the European coastal

110 tes for >60 cells/h with a resolution of 0.2 pg/h for mammalian cells and 0.02 pg/h for bacteria.

111 of detection of IL-6 in human sweat was 0.2 pg/mL for 0-24 hours and 2 pg/mL for 24-48 hours post-an

112 (ULISA) reaches a limit of detection of 1.2 pg mL(-1) (42 fM) PSA in 25% blood serum, which is about

113 higher in subjects with detectable VL (108.2 pg/mL) as compared to those with undetectable VL (38.0 p

114 Using a cutoff value of IP-10 >/=44.2 pg/mL, the model identified detectable VL with 91.9% sen

115 ice meltwater samples (224-253 and 34.7-48.2 pg.L(-1) respectively compared to 1.0-1.3 and <0.63 pg.L

116 mL-10 ng/mL with a limit of detection of 8.2 pg/mL.

117 g IFNG/mL (inter-quartile range, 100.4-920.2 pg IFNG/mL) (P = .0002).

118 The polyester powder contained 6 pg/g and 2 pg/g for (232)Th and (238)U, respectively.

119 ere typically below 1 pg/g for (232)Th and 2 pg/g for (238)U, corresponding to 4 and 25 muBq/kg radio

120 man sweat was 0.2 pg/mL for 0-24 hours and 2 pg/mL for 24-48 hours post-antibody sensor functionaliza

121 LPS (6.0 [4.0-17.5] versus 57.4 [43.4-87.2] pg/mL, P < 0.0001), soluble cluster of differentiation 4

122 an create NGS libraries from as little as 20 pg DNA with PCR error correcting capabilities, and captu

123 rbance detection at 214 nm, equivalent to 20 pg of protein (330 attomole) loaded in the autosampler v

124 pg/ml [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR: 827 to 1,807 pg/ml], respectively; p < 0.001

125 Continuous detection of IL-6 over 0.2-200 pg/mL in human sweat was demonstrated for a period of 10

126 eceptor-free bilayers at doses as low as 200 pg/ml in a wide range of pH (5.5-9.5) and without the ne

127 nd -900, -6400 and -400, and -1400 and -200 (pg.m(-2).d(-1)) for gamma-HCH, dieldrin, and chlorpyrifo

128 hexyl diphenyl phosphate (EHDPP; 610 +/- 220 pg m(-3)) measured in TSP samples were significantly hig

129 iagnosed cases (mean decline difference 2231 pg/dl, 95% CI: 897-3566, p = 0.0013).

130 re pathway to FRs (median total exposure 230 pg/kg bw/d, accounting for more than 65% of the total ex

131 High concentrations of up to 2340 pg m(-3) were observed for Tri-n-butyl phosphate (TnBP)

132 e 4-70 pg/cell with higher levels (up to 238 pg/cell) being found in strains from the Ligurian and So

133 atients with HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778

134 range [IQR], 1.43-2.67 pg/mL vs median, 2.25 pg/mL; IQR, 1.63-3.08 pg/mL, P < 0.001; and for IL6: med

135 he highest median concentrations (150 and 25 pg/m(3) (sum of alpha- and beta-isomers), respectively).

136 Mix, enabling accurate quantification for 25 pg/nL HA.

137 0 fL, reticulocyte hemoglobin equivalent >25 pg, serum ferritin level >15 ng/mL, and total iron-bindi

138 but not placental-like growth factor (>/= 25 pg/mL; adjusted hazard ratio, 1.26; 95% confidence inter

139 157.0 (154.0) pg/mL, Group II: 98.0 (20.25) pg/mL, P = .01); and vitamin D (VDBP) (Group I: 0.06 (0.

140 d (median [interquartile range] 13 [7 to 25] pg/mol vs. 18 [9 to 36] pg/mol; p < 0.001; n = 340).

141 olds were a brain-type NP (BNP) level of 250 pg/mL or less or an amino-terminal pro-brain-type NP (NT

142 or B-type natriuretic peptide levels of 250 pg/mL or more, regardless of ejection fraction.

143 highest mean (SD) serum sIL-2R (6047 [2533] pg/mL) and ACE (61 [38] U/L) levels, elevated serum sIL-

144 L) in those with AF and 1271 pg/mL (703-2569 pg/mL) in those without (P<0.0001).

145 he mean concentration of IL-2 (5.56 +/- 1.27 pg/mL) was significantly lower in the NAION group than i

146 imal cutoffs, high levels of sFlt-1 (>/= 280 pg/mL; adjusted hazard ratio, 1.47; 95% confidence inter

147 2 months of age) than nontransmitters (20.29 pg/mL vs 19.41 pg/mL; P = .005).

148 cm or volume >/=58 mL) or increased (>/=290 pg/mL) serum NT-proBNP (N-terminal pro-B-type natriureti

149 versus 11.4 per 100 patient-year; 2000-2999 pg/mL, 13.5 versus 13.4 per 100 patient-years; >/=3000 p

150 ute concentrations (25 +/- 6 versus 16 +/- 3 pg/mL).

151 in FC (24.1 pg/mL (13.5-51.8)) and NC (19.3 pg/mL (13.6-35.2)) than in healthy controls (7.9 pg/mL (

152 of 1.7, 0.17, 5.7, 0.57, 1.8, 0.18, and 2.3 pg kg bw(-1) day(-1) were obtained in residential indoor

153 pg kg bw(-1) day(-1)) and personal air (3.3 pg kg bw(-1) day(-1)) were both around 5 orders of magni

154 (p < 0.05), and 336.3 [211.0-403.2] to 385.3 pg/mL [283.4-517.3] in non-responders at baseline and 6

155 nd median TF levels were 72.5 pg/mL and 50.3 pg/mL, respectively (range, 15.6 pg/mL to 4,798 pg/mL).

156 a 50 s period, equivalent to approximately 3 pg of sampled material.

157 bited a wide cortisol-detection range from 3 pg/mL to 10 mug/mL, with a sensitivity of 50 Omega (pg m

158 detect cortisol with a detection limit of 3 pg/mL was achieved by conjugating anticortisol antibody

159 ge of male but not female rats and DAMGO (30 pg) produced no further inhibition of female LC neurons.

160 se without (1,500 pg/ml [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR: 827 to 1,807 pg/ml], respec

161 o </=300 pg/mL; n = 112), and high PTH (>300 pg/mL; n = 134) and underwent repeated, longitudinal tes

162 hyroid hormone (PTH), low PTH (>65 to </=300 pg/mL; n = 112), and high PTH (>300 pg/mL; n = 134) and

163 ortion of patients achieving mean PTH of 300 pg/mL or lower.

164 ly more likely to achieve a PTH level of 300 pg/mL or lower: in trial A, 126 of 254 (49.6%) vs 13 of

165 5 versus 13.4 per 100 patient-years; >/=3000 pg/mL, 22.7 versus 23.0 per 100 patient-years).

166 ce), 1000 to 1999, 2000 to 2999, and >/=3000 pg/mL.

167 L) than in convalescent samples (314 and 311 pg/mL at 7 and 30 days, P < .001).

168 ential indoor air were 2970, 10400, and 3120 pg m(-3) for 6:2, 8:2, and 10:2 FTOH, respectively.

169 r PCBs (iPCBs) in air ranged from 54 to 3160 pg.m(-3) in the two sampling campaigns (spring 2011 and

170 L in patients with a BMI <25 kg/m(2) and 319 pg/mL in patients with a BMI >35 kg/m(2) (P<0.001).

171 uretic peptide concentration (403 versus 320 pg/mL; all P<0.01), more signs of congestion, but no sig

172 vels of NT-proBNP were 1817 pg/mL (1095-3266 pg/mL) in those with AF and 1271 pg/mL (703-2569 pg/mL)

173 peptide (NT-proBNP; 191 +/- 261 vs 33 +/- 33 pg/mL, P = .04) but lower hemoglobin (8.4 +/- 0.3 vs 10.

174 in NT-proBNP serum levels (-250 [-1465; 33] pg/mL; relative reduction -24%) 4 months after BMC admin

175 nd exhibited a small genome size (1 C = 0.34 pg), an annual life cycle, and greater genetic diversity

176 In support of these predictions, up to 3400 pg L(-1) of FOSA and up to 1100 pg L(-1) of PFOS were me

177 FOSA) were routinely detected (range: <5-343 pg/L).

178 lower amount of amiodarone at 0.43 and 0.36 pg per cell, respectively.

179 r PFOS based on North Atlantic inflow (11-36 pg/L) agreed with measurements (mean, 17, range <5-41 pg

180 range] 13 [7 to 25] pg/mol vs. 18 [9 to 36] pg/mol; p < 0.001; n = 340).

181 torPFAS) in freshly deposited snow (760-3600 pg L(-1)) were 1 order of magnitude higher than those in

182 ial A; corresponding values were 845 and 363 pg/mL vs 852 and 960 pg/mL in trial B.

183 hereas Immolase (1 U) could handle up to 375 pg/nL HA.

184 roup (tissue necrosis factor: 26.95 vs 18.38 pg/mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p

185 line and during weeks 20-27 were 849 and 384 pg/mL vs 820 and 897 pg/mL in the etelcalcetide and plac

186 rvival (n = 106) (median, 36.0 pg/mL vs 10.4 pg/mL, respectively, P < .001).

187 ted peptides with LOD and LOQ at 1.2 and 2.4 pg, respectively, and high reproducibility with interday

188 ebo, at day 90 (-27.1+/-10.9 vs. 46.5+/-30.4 pg/ml; P = 0.02).

189 he mean concentration of VEGF (94.1 +/- 40.4 pg/mL) was significantly higher in the NAION group compa

190 ue 13.7 ng/ml) and IL-6 (cut-off value 473.4 pg/ml) were reliable early markers of SAP.

191 [SD] log CXCL10, from 2.4 [0.4] to 2.2 [0.4] pg/mL; P = .03).

192 eruginosa (11.5 [5.4-21.8] vs. 2.8 [0.9-9.4] pg/mL, p < 0.01) and was significantly elevated within 3

193 natriuretic peptide levels (defined as >400 pg/mL; odds ratio 1.80; 95% CI, 1.21-2.68) in adjusted m

194 with and without AF in the lowest band (<400 pg/mL; 8.2 versus 5.0 per 100 patient-years), but not fo

195 However, above a concentration of 400 pg/mL (representing most patients in each group), NT-pro

196 (TEQ) loading of dioxin-like pollutants (400 pg TEQ m(-2) y(-1)) compared to Marseille ( approximatel

197 , corresponding to an optimal cutoff of 4000 pg/mL and providing 81% (95% CI, 74%-89%) sensitivity an

198 ) than nontransmitters (20.29 pg/mL vs 19.41 pg/mL; P = .005).

199 /- 129 pg/mL before treatment and 241 +/- 41 pg/mL after treatment (p < 0.001).

200 eed with measurements (mean, 17, range <5-41 pg/L).

201 summation operatorPFAS ranged from 94 to 420 pg L(-1) in seawater and from 3.1 to 16 ng gdw(-1) in pl

202 e exhibited a larger genome size (1 C = 0.43 pg), a perennial lifecycle, less chloroplast genetic div

203 rather than personal air concentrations (43 pg/kg bw/d versus 130 pg/kg bw/d).

204 han those in background surface snow (82-430 pg L(-1)).

205 a single test, an IL-6 cut-off level of 432 pg/mL on day 1 yielded a specificity of 70% and a sensit

206 ly adjusted model, each 1-SD increment (0.44 pg/ml) of log NT-proBNP was associated with a 0.62% incr

207 with concentrations ranging from 360 to 4400 pg m(-3) for the sum of compounds.

208 kin-1beta, 226.8 +/- 27.1 vs. 182.5 +/- 21.5 pg mg(-1) ; P < 0.05) in the brain, and the mortality ra

209 Mean and median TF levels were 72.5 pg/mL and 50.3 pg/mL, respectively (range, 15.6 pg/mL to

210 sensor exhibited a wide working range from 5 pg/mL to 100 ng/mL with a minimum detection limit of 1 p

211 ) were slightly higher than measurements (<5 pg/L), suggesting the lower bound of PFAS emissions esti

212 ghly functional, even at concentrations < 50 pg/ml.

213 ian PCSK9 compared with those without (1,500 pg/ml [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR:

214 atients with NT-proBNP concentrations of 500 pg/mL or higher.

215 with 100 cross-linked cells for ChIP or 500 pg of genomic DNA for MeDIP (compared to 10(6)-10(7) cel

216 hormone (PTH) concentrations higher than 500 pg/mL on active therapy at 164 sites in the United State

217 y (SNIA) was found to be between 0.02 to 500 pg/mL in a linear dose dependent manner.

218 NT-proBNP was 500 pg/mL or higher in 465 (30%) of 1565 patients given edox

219 lasma levels (median, 23 376.49 vs 18 476.52 pg/mL; P = .03) and worse treatment-related toxic effect

220 fungal meningitides ranged from 86 to 1,524 pg/ml CSF, with 37 controls of <4 to 115 pg/ml CSF.

221 ors (n = 19 of 26), at levels ranging 31-547 pg/mL.

222 worse outcome (P= .009); a ratio of >/=0.55 pg/mL had high specificity and sensitivity for a poor ou

223 MAs(V), and DMAs(V) were 40, 97, 57, and 55 pg mL(-1), respectively.

224 levels of brain natriuretic peptide were 550 pg/mL in patients with a BMI <25 kg/m(2) and 319 pg/mL i

225 ropospheric air of 198 +/- 57 and 229 +/- 58 pg m(-3) which agree well with in-flight observed RM and

226 , 0.030 ug (95% CI = 0.026, 0.034) and 0.592 pg (95% CI = 0.488, 0.696).

227 , NT-proBNP levels (159; 95% CI, -280 to 599 pg/mL), or KCCQ score (1; 95% CI, -2.4 to 4.4), all P >

228 latitude from 7.7 to 3.0 and from 1.0 to 0.6 pg.L(-1), respectively.

229 n did 103 CFU/mL (4.4 +/- 1.8 vs 1.0 +/- 0.6 pg/mL; P < .01).

230 < 0.001) and from 4.2 +/- 1.4 to 2.8 +/- 1.6 pg/mL (P < 0.01), respectively.

231 mL and 50.3 pg/mL, respectively (range, 15.6 pg/mL to 4,798 pg/mL).

232 erienced the greatest VTE recurrence (> 64.6 pg/mL; 38 [19%] of 203 patients v 34 [6%] of 602 patient

233 The polyester powder contained 6 pg/g and 2 pg/g for (232)Th and (238)U, respectively.

234 inearity for DA from 0.05-100 ng/mL (LOD = 6 pg/mL) and DOPAC from 0.5-100 ng/mL (LOD = 162 pg/mL).

235 = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001).

236 amiodarone with an average of 2.38 and 2.60 pg per cell, respectively, and HeLa and Hek 293 have a s

237 sfect B lymphocytes, and induce more than 60 pg of protein expression per million B cells within the

238 phy combined with sIL-2R at a cutoff of 6000 pg/mL resulted in 77% sensitivity and 73% specificity.

239 ) respectively compared to 1.0-1.3 and <0.63 pg.L(-1) respectively for Antarctic samples).

240 an (SD) endothelin-1 levels were 1.36 (0.64) pg/mL; 217 of 3223 cohort members (6.7%) had pulmonary h

241 eased (from 178 [116, 217] to 509 [340, 648] pg/mL).

242 ant, persistent hyperparathyroidism (PTH >65 pg/mL) was 89.5%, 86.8%, 83.1%, and 86.2%, at months 3,

243 antly higher during anaphylaxis (median, 658 pg/mL) than in convalescent samples (314 and 311 pg/mL a

244 ccurrence of summation operator6DDT (0.10-66 pg L(-1)) in the surface water was dominated by 4,4'-DDE

245 estrel concentrations were 580, 247, and 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups

246 0.5 to 194 ng/m(3) (PCBs) and from 4 to 665 pg/m(3) (OH-PCBs).

247 pg/mL; interquartile range [IQR], 1.43-2.67 pg/mL vs median, 2.25 pg/mL; IQR, 1.63-3.08 pg/mL, P < 0

248 10 was detected at lower levels ranging 3-69 pg/mL.

249 the developed sensor was calculated as 2.6Hz/pg.

250 In addition, a 1.7 pg (0.024 femtomoles) limit of detection for clinical sa

251 onary hypertension and low endothelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonary hypertension and

252 high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary hypertension and low e

253 FOA intakes from residential indoor air (5.7 pg kg bw(-1) day(-1)) and personal air (3.3 pg kg bw(-1)

254 [0-18.1] pg/mL) and controls (4.8 [0.3-17.7] pg/mL).

255 Toxin content was mostly in the range 4-70 pg/cell with higher levels (up to 238 pg/cell) being fou

256 estrel concentrations were 528, 280, and 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups

257 of patients with E2 levels greater than 2.72 pg/mL at any time point during treatment with exemestane

258 2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal

259 0.84), and (3) sRAGE (optimal cutoff, 11 760 pg/mL; AUC, 0.66; 95% CI, 0.41-0.91) measured at H0.

260 igh-dose spironolactone and 3753 (1968-7633) pg/mL among the group who received usual care.

261 up of 46 months, LGE-positive and FT3 < 2.77 pg/mL was identified as the strongest predictor of cardi

262 mL, respectively (range, 15.6 pg/mL to 4,798 pg/mL).

263 6.4 vs OW/OB 73.8+/-31.3 vs HC 199.5+/-167.8 pg/ml, p=0.01), despite comparable mean serum progestero

264 ared to the cataract controls (52.2 +/- 20.8 pg/mL; P = .010) and the mean concentration of IL-2 (5.5

265 ollow up (Baseline 38.8 pg/L, follow up 30.8 pg/L p = 0.02).

266 onin T was lower at follow up (Baseline 38.8 pg/L, follow up 30.8 pg/L p = 0.02).

267 00 pg/ml] vs. 1,200 pg/ml [IQR: 827 to 1,807 pg/ml], respectively; p < 0.001).

268 pg/mL; IQR, 1.21-3.02 pg/mL vs median, 2.81 pg/mL; IQR, 1.65-4.97 pg/mL, P < 0.001).

269 mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/

270 percentiles) klotho level was 630 (477, 817) pg/ml.

271 up but decreased significantly by 774 +/- 85 pg/mL in HF+ELA dogs (P<0.001).

272 o-brain natriuretic peptide [NTproBNP] >8500 pg/mL) disease, VWF:Ag identified subgroups of patients

273 /mL, p = 0.02; interleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p

274 , [63.14-177.89] versus 20.29, [15.00-53.89] pg/mL, P<0.001) and significantly decreased vascular end

275 20-27 were 849 and 384 pg/mL vs 820 and 897 pg/mL in the etelcalcetide and placebo groups, respectiv

276 and 2014 at an average annual rate of -14.9 pg g(-1) wet weight.

277 L (13.6-35.2)) than in healthy controls (7.9 pg/mL (5.6-17.2)) (OR=5.85; 95% CI 2.63 to 13.02; p = 1.

278 L, and epinephrine rose to approximately 900 pg/mL.

279 pg/mL, P < 0.001; and for IL6: median, 1.91 pg/mL; IQR, 1.21-3.02 pg/mL vs median, 2.81 pg/mL; IQR,

280 than in the control group (313.88 vs 337.91 pg/mL, p = 0.0078).

281 he follow-up period (TNF-alpha: median, 1.92 pg/mL; interquartile range [IQR], 1.43-2.67 pg/mL vs med

282 (3.3-10.5) ng/L for hs-cTnI and 39 (15, 94) pg/mL for BNP.

283 35 pg/ml; p < 0.0001) and 63% (1970.3 +/- 95 pg/ml; p < 0.001).

284 ange) NT-proBNP levels were 4601 (2697-9596) pg/mL among the group treated with high-dose spironolact

285 values were 845 and 363 pg/mL vs 852 and 960 pg/mL in trial B.

286 pg/mL vs median, 2.81 pg/mL; IQR, 1.65-4.97 pg/mL, P < 0.001).

287 iuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0.0069).

288 ears), but not for the higher bands (400-999 pg/mL, 7.4 versus 7.7 per 100 patient-years; 1000-1999 p

289 abled the detection of cardiac troponin I at pg/mL concentrations in 10% serum without significant ma

290 uated by analyzing spiked urine at different pg/mL concentration levels.

291 P=0.039), but not in 100 million (-0.07 log pg/mL; 95% CI, -0.36 to 0.23; P=0.65; between group P=0.

292 eased at 12 months in 20 million by 0.32 log pg/mL (95% CI, 0.02 to 0.62; P=0.039), but not in 100 mi

293 (3.63 [SD 0.54] log pg/mL vs 2.68 [0.52] log pg/mL, p<0.0001) and the difference increased from one d

294 arriers than in controls (3.63 [SD 0.54] log pg/mL vs 2.68 [0.52] log pg/mL, p<0.0001) and the differ

295 follow-up period (hazard ratio 3.29 per log pg/mL, 95% CI 1.48-7.34, p=0.0036).

296 he most disadvantaged pregnancies [-1.53 log(pg/mL); 95% CI: -1.81, -1.25].

297 o 10 mug/mL, with a sensitivity of 50 Omega (pg mL(-1))(-1).

298 and found them to be capable of quantifying pg/mL concentrations of soluble or cell-bound HER2, prov

299 vely measure biomarkers electrochemically to pg/ml range with insignificant nonspecific binding and f

300 gh tracer recoveries and detection limits to pg/g (i.e., parts per trillion) levels or below, corresp